TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...

Infliximab is a manufactured antibody made of living cells and is a type of medication called a biologic. It works by targeting a protein called tumor necrosis factor-alpha (TNF-alpha).

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

The results of this trial prompted the FDA to approve infliximab as a treatment for moderate to severe ulcerative colitis.

Usually managed with steroids and antihistamine, occasionally requiring a change of anti-TNF agent. Infliximab is associated with infusion reactions (approximately 10% - usually mild). 1,2 ...

Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36 , 1681–1690 (1993). Article CAS Google Scholar ...

Both Remicade and Humira have equal effictiveness ... monoclonal antibody that works by blocking tumor necrosis factor alpha ...

Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine and peripheral joints that can lead to significant disability if left untreated. Conventional treatments can be ...

Normally, this is a tumour necrosis factor (TNF)-alpha inhibitor (usually, infliximab). Clinical experts recommend that TNF-alpha inhibitors be used alongside thiopurines for maximum efficacy.